Rolapitant - CAS 552292-08-7
Catalog number: B0084-479245
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C25H26F6N2O2
Molecular Weight:
500.49
COA:
Inquire
Targets:
Others
Description:
Rolapitant is a selective NK1 receptor antagonist (antagonist for the NK1 receptor).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-479245 300 mg $388 In stock
Bulk Inquiry
Purity:
>95%
Related CAS:
914462-92-3 (hydrochloride); 552292-08-7 (free base)
Appearance:
Solid Powder
Synonyms:
(5S,8S)-8-(((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro[45]decan-2-one; SCH619734; SCH-619734; SCH 619734; Varubi
MSDS:
Inquire
Quantity:
Milligrams-Grams
InChIKey:
FIVSJYGQAIEMOC-ZGNKEGEESA-N
InChI:
InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1
Canonical SMILES:
CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4
1.Effects of Rolapitant Administered Intravenously on the Pharmacokinetics of a Modified Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan) in Healthy Subjects.
Wang X;Zhang ZY;Arora S;Wang J;Lu S;Powers D;Kansra V J Clin Pharmacol. 2018 Apr 25. doi: 10.1002/jcph.1114. [Epub ahead of print]
Rolapitant is a selective, long-acting neurokinin-1 receptor antagonist, approved in the United States and Europe for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This open-label study evaluated the effects of a new intravenous formulation of rolapitant on cytochrome P450 (CYP) enzyme (CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2D6) activity. On days 1 and 14, 36 healthy volunteers received a modified Cooperstown cocktail (midazolam 3 mg [CYP3A substrate], caffeine 200 mg [CYP1A2 substrate], S-warfarin 10 mg [CYP2C9 substrate] + vitamin K 10 mg, omeprazole 40 mg [CYP2C19 substrate], and dextromethorphan 30 mg [CYP2D6 substrate]). On day 7, subjects received the modified Cooperstown cocktail after 166.5-mg rolapitant infusion. On days 21, 28, and 35, subjects received oral dextromethorphan. Maximum plasma concentration (C;max; ) and area under the plasma concentration-time curve (AUC;0-last; ) of probe drugs post- vs pre-rolapitant administration were assessed using geometric least-squares mean ratios (GMRs) with 90%CIs. The 90%CIs of the GMRs were within the 0.80-1.25 no-effect limits for caffeine and S-warfarin C;max; and AUC;0-last; . For midazolam C;max; and AUC;0-last; and omeprazole C;max; , the 90%CIs of the GMRs were marginally outside these limits.
2.Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
Reddy GK;Gralla RJ;Hesketh PJ Support Cancer Ther. 2006 Apr 1;3(3):140-2. doi: 10.3816/SCT.2006.n.011.
Despite significant advances in supportive care in oncology, many patients with cancer still experience chemotherapy- induced nausea and vomiting (CINV). Historically, there were only 3 neurotransmitter receptors (dopamine D2, cannabinoid- 1, and 5-hydroxytryptamine-3) that were the known targets for antiemetic therapy. Major advances in the management of chemotherapy-induced emesis were seen with the introduction of 5-hydroxytryptamine-3 receptor antagonists, which include palonosetron, ondansetron, tropisetron, dolasetron, and granisetron. However, recently, selective inhibitors of substance P have shown promising activity in the management of CINV in patients with cancer. Substance P mediates a number of biologic effects by binding to a specific neuroreceptor, neurokinin-1 (NK-1). Among the NK-1 receptor antagonists, aprepitant has been approved for the treatment of CINV. Currently, several other NK-1 receptor antagonists, including casopitant, vestipitant, netupitant, and SCH619734, are undergoing clinical evaluation for the prevention of CINV in patients with a variety of malignancies. The clinical potential of these novel NK-1 receptor antagonists and their respective ongoing clinical trials for the management of chemotherapy-induced emesis are discussed briefly herein.
3.Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
Jordan K;Jahn F;Aapro M Ann Oncol. 2015 Jun;26(6):1081-90. doi: 10.1093/annonc/mdv138. Epub 2015 Mar 9.
The prevention of chemotherapy-induced nausea and vomiting (CINV) has been revolutionized over the past 25 years. Guideline-based treatment means that vomiting can be prevented in the majority, but not in all patients. Therefore, antiemetic research continues with the goal of optimizing CINV control for all patients. This comprehensive review summarizes the research efforts in this field over the past few years. Emerging from this research are two new antiemetic agents, netupitant/palonosetron, the first antiemetic combination agent and rolapitant, a new NK1RA. In addition, studies have evaluated the benefits of olanzapine and ginger, explored optimal combinations of agents for delayed CINV prevention, confirmed that dexamethasone-sparing regimens are effective, and demonstrated the value of NK1RAs in high-dose chemotherapy settings as well as with certain moderately emetogenic chemotherapies such as carboplatin. Research has also validated the correlation between antiemetic guideline adherence and improved CINV control. Finally, regulatory authorities have utilized extreme caution in retiring some 5-HT3RAs or decreasing their maximum dose.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 34597-40-5 Fenoprofen Calcium

Fenoprofen Calcium
(CAS: 34597-40-5)

Fenoprofen Calcium is a nonsteroidal, anti-inflammatory antiarthritic agent.

KHK-IN-1
(CAS: 1303469-70-6)

KHK-IN-1, a pyrimidinopyrimidine derivative, is a ketohexokinase inhibitor that could have probable effect against diabetes and obesity by acting on Asp-27B in ...

CAS 314728-85-3 Sunifiram

Sunifiram
(CAS: 314728-85-3)

unifiram (DM-235) is a piperazine derived research chemical which has nootropic effects in animal studies with significantly higher potency than piracetam.

Z-Ile-Glu-Pro-Phe-Ome
(CAS: 252557-97-4)

Z-Ile-Glu-Pro-Phe-Ome is a peptide inhibitor of human heart chymase which is a chymotrypsin-like enzyme that converts angiotensin I to angiotensin II.

CAS 883226-64-0 S 07662

S 07662
(CAS: 883226-64-0)

S 07662 is an inverse agonist of the constitutive androstane receptor (CAR). S 07662 inhibits CAR activity via recruitment of nuclear receptor co-repressor (NCo...

CAS 124190-19-8 FR 901235

FR 901235
(CAS: 124190-19-8)

This active molecular is an immunoactive substance that produced by Paecilomyces carneus F-4882, an imperfect fungus. FR-901235 can lead to the mitogen-induced ...

CAS 5072-26-4 Buthionine Sulphoximine

Buthionine Sulphoximine
(CAS: 5072-26-4)

Buthionine Sulphoximine, also known as NSC-326231, is a potent and specific inhibitor of alpha-glutamyl cysteine synthetase.

CAS 474-86-2 Equilin

Equilin
(CAS: 474-86-2)

Equilin is one of the estrogens present in the mixture of estrogens isolated from horse urine and marketed as Premarin.

Chemical Structure

CAS 552292-08-7 Rolapitant

Quick Inquiry

Verification code

Featured Items